ABOUT OFF-X

Unexpected toxicity and safety issues constitute one of the most disruptive events in drug R&D, with one third of drug attrition still directly related to these events. In this context, a translational approach to drug safety and prompt access to actionable safety intelligence can significantly reduce patient burden and avoid costly failures.

Since 2017, the Bioinfogate OFF-X^TM portal has been supporting translational researchers in pharmaceutical and healthcare organizations to de-risk drug R&D programs.

By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, Bioinfogate OFF-X^TM allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing

Rapid access to actionable safety intelligence via OFF-X provides a critical competitive advantage for your R&D:

Time saving: OFF-X reduces the time and resources required to retrieve critical safety intelligence. OFF-X breaks information silos by comprehensively integrating disparate sources of data with a fast turnaround.
Comprehensiveness: OFF-X’s extensive coverage of information sources provides daily access to key data that is not readily available and that may not be published elsewhere after a first mention, for example a reference in a scientific congress.
OFF-X covers all phases of drug R&D, including first-in-class and emerging targets.
OFF-X provides a unique translational approach: used across a wide range of departments and facilitates the translational safety intelligence paradigm by interconnecting and integrating critical safety intelligence form early target discovery to post-marketing and patient safety.

About Bioinfogate

BIOINFOGATE is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and also identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.

Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007), acquired by Thomson Reuters in 2007 (now Clarivate Analytics), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.